Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept for wet age-related macular degeneration: 3+PRN versus treat-and-extend
ChiCTR2100053627Phase 4Recruiting
- Sponsor
- Xi'an First Hospital
- Start
- Dec 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept in exudative macular degeneration (2 arms), sponsored by Xi'an First Hospital. Primary endpoints: Best-corrected visual acuity at 12 months, Thickness of central retina of macula at 12 months and 2 more. Started Dec 2021; status: recruiting.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2100053627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053627.